Beacon Financial Corporation reported net income of $61.2 million for the third quarter of 2026, a significant recovery from a net loss of $4.2 million in the same period of 2025. The company experienced substantial growth in net interest income following its merger transaction, though it faced a decrease in total assets from $23.2 billion at year-end 2025 to $21.9 billion at September 30, 2026.
Voya Retirement Insurance and Annuity Company reported a net income of $435 million for the nine months ended September 30, 2026, a slight decrease from $438 million in the prior year. Total assets increased to $149.98 billion, primarily driven by growth in separate account assets, though total shareholder's equity declined significantly to $1.59 billion due to $900 million in after-tax unrealized losses on investments.
Nuveen Global Cities REIT reported total revenues of $166.5 million for the nine months ended September 30, 2026, compared to $158.3 million in the prior year period. Net income attributable to common stockholders significantly improved to $15.6 million from $0.4 million year-over-year, primarily driven by higher rental revenues and a reduction in total other expenses.
MainStreet Bancshares reported net income of $12.4 million for the first nine months of 2026, an increase from $11.6 million in the prior year period. Total assets grew slightly to $2.23 billion, while the company executed significant common stock repurchases totaling $11.1 million during the period.
CNH Industrial Capital LLC reported a net income of $52.3 million for the third quarter of 2026, a decrease from $58.7 million in the prior year period. Total revenues declined slightly to $328.4 million, while the provision for credit losses increased to $29.7 million from $22.1 million year-over-year.
Claritev Corporation reported a net loss of $61.8 million for the third quarter of 2026, an improvement from the $69.8 million loss in the prior year period, driven by a 9% increase in revenues to $268.3 million. Despite higher operating income, the company remains heavily burdened by $100.9 million in quarterly interest expense and carries a total shareholders' deficit of $339.9 million.
For the quarter ended September 30, 2026, CNH Industrial reported total revenues of $4.35 billion, a slight decrease from $4.40 billion in the prior year. Net income attributable to the company fell to $30 million ($0.02 per share) compared to $80 million ($0.06 per share) in 2025, primarily impacted by a significantly higher income tax expense during the period.
Regions Financial Corporation reported 848,847,340 shares of common stock outstanding as of November 6, 2026. The filing outlines significant risk factors including market interest rate fluctuations, credit losses, and potential weaknesses in residential and commercial real estate markets.
Golden Growers Cooperative reported net income of $4.2 million for the nine months ended September 30, 2026, a slight decrease from $4.5 million in the prior year. The Cooperative's financial position remains influenced by its 50% interest in ProGold LLC, which contributed $4.67 million in net income during the period, while members' equity decreased to $13.6 million following $10.7 million in distributions.
Trinseo PLC filed for Chapter 11 bankruptcy on May 26, 2026, to facilitate a comprehensive capital restructuring. As of September 30, 2026, the company reported total assets of $2,456.6 million and a significant increase in short-term borrowings and current debt to $589.6 million compared to $212.9 million at year-end 2025.
ChoiceOne Financial Services reported net income of $40.7 million for the first nine months of 2026, a significant increase from $14.3 million in the same period of 2025, which was impacted by $17.4 million in merger-related expenses. Total assets grew slightly to $4.46 billion, while the company experienced a notable increase in accumulated other comprehensive loss due to unrealized losses on available-for-sale securities.
The Marygold Companies reported financial results for its first fiscal quarter ended September 30, 2026, with revenue increasing to $9.4 million from $5.2 million in the prior year. The company swung to a net income of $1.8 million ($0.04 per share) compared to a net loss of $0.4 million a year ago, driven largely by strong growth at its USCF Investments subsidiary. Management also highlighted the pending acquisition of the company by Madison Dearborn Partners for $2.00 per share, expected to close in the first half of 2027.
Term
Q1 2027
“During the quarter, the Company announced it had entered into a definitive merger agreement under which funds managed by Madison Dearborn Partners will acquire all of the outstanding shares of The Marygold Companies for $2.00 per share, representing a premium of 100% over the Company’s closing share price on September 24, 2026, the day before the agreement was announced. The transaction is expected to close during the first half of 2027, or earlier, upon satisfaction of a number of closing conditions that are usual and customary for transactions of this nature.”
Nicholas Gerber, Chief Executive Officer
“Revenues and income increased significantly for the first quarter, primarily reflecting the increased activity in energy related ETFs, due in part to the Iran war. Our other non-financial services operations, including discontinued operations in New Zealand, were also profitable during the first quarter. However, our UK investment advisory businesses recorded a net loss of $0.1 million for the quarter as compared with a net loss of $0.4 million for the prior year quarter, showing a significant reduction in expenses associated with the mobile fintech banking app now on pause.”
Delcath Systems reported a significant increase in product revenue to $89.2 million for the first nine months of 2026, resulting in a net income of $8.6 million compared to $4.6 million in the prior year. The company maintained a strong liquidity position with $104.3 million in cash and short-term investments as of September 30, 2026.
AiXin Life International reported a total revenue of $211,527 for the three months ended March 31, 2026, a significant decrease from $398,831 in the prior year period. The company incurred a net loss of $531,728 and continues to operate with a substantial stockholders' deficit of over $7.1 million.
Telos Corporation reported its third quarter 2026 financial results for the period ended September 30, 2026. The company hosted a conference call and webcast to discuss the results and provided supplemental presentation materials on its investor relations website.
United-Guardian reported strong third quarter 2026 results with net sales increasing 54% to $3.5 million and net income surging 247% to $0.93 million. Growth was driven by a 187% increase in cosmetic ingredient sales and a 29% rise in pharmaceutical sales, specifically for its lead product Renacidin.
Term
Q3 2026
“I am very excited to report that our third quarter was exceptionally strong, with pharmaceuticals, personal care and medical lubricants all posting sales increases. Pharmaceutical sales grew 29% compared with the same period in 2025, driven primarily by Renacidin®, our most important pharmaceutical product.”
Donna Vigilante, President of United-Guardian
“I am very pleased with our performance for the first nine months of 2026. Our growth initiatives have produced encouraging results, and we plan to continue building on this progress.”
Heron Therapeutics filed its 10-Q for the period ended September 30, 2026, reporting 190,273,587 shares of common stock outstanding. The filing highlights a pending Asset Sale to CorMedix and notes significant risks regarding the company's ability to continue as a going concern without additional funding.
ContextLogic Holdings Inc. reported a net loss of $13.4 million for the three months ended September 30, 2026, compared to a net income of $3.0 million in the prior year period. The company underwent a significant transition from a Predecessor to a Successor entity in February 2026, marked by substantial acquisitions and a rights offering that increased total assets to $964.9 million.
Mereo BioPharma reported a net loss of $19.6 million for the nine months ended September 30, 2026, an improvement from the $34.5 million loss in the prior year period. Cash and cash equivalents decreased to $26.1 million from $41.0 million at the end of 2025, primarily driven by research and development expenses for its rare disease clinical programs.
Quanterix Corp reported total revenues of $104.3 million for the nine months ended September 30, 2026, a 10% increase year-over-year, though it recorded a net loss of $88.1 million. The company's financial position was impacted by $46.9 million in impairment and restructuring costs and a significant decrease in marketable securities from $88.4 million to $41.5 million since the end of 2025.
Fervo Energy reported Q3 2026 financial results, highlighting the achievement of commercial operation at its 33-megawatt Cape Station Phase I GeoBlock 1. The company also signed a major 396-megawatt power purchase agreement with Google, with an option to expand the partnership to nearly 1 gigawatt.
“In the third quarter, Cape Station achieved a major milestone, reaching first power and contractual commercial operation. We also signed what we believe is the largest enhanced geothermal power purchase agreement to date with Google, creating a pathway to scaling our partnership to nearly a gigawatt.”
ContextLogic Holdings Inc. reported Q3 2026 revenue of $32.2 million, which was flat year-over-year as higher average sales prices were offset by a 5.7% decrease in volume due to trucking availability constraints. The company reported a net loss of $13.4 million, driven by corporate platform costs and increased amortization following its acquisition of US Salt earlier in the year.
Term
Q3 2026
“Shipments this quarter were again constrained by limited trucking availability, and we are working to address this directly and proactively. We have numerous initiatives in flight to improve outbound freight, including a drop and hook program, and we are beginning to see early signs of progress.”
For the nine months ended September 30, 2026, Ionis Pharmaceuticals reported total revenue of $756.8 million, a slight increase from $740.4 million in the prior year, driven by higher commercial product sales. However, the company's net loss widened significantly to $317.1 million compared to $152.0 million in 2025, primarily due to a substantial increase in selling, general, and administrative expenses.
Ecopetrol S.A. reported a significant increase in net profit for the first half of 2026, reaching 11,316 billion Colombian pesos compared to 7,618 billion in 2025, driven by higher sales revenue of 68,823 billion pesos. Despite improved operating income, the company faced substantial negative foreign currency translation adjustments in other comprehensive income, totaling 6,296 billion pesos.
Tonix Pharmaceuticals reported a significant increase in product revenue to $37.7 million for the first nine months of 2026, up from $7.7 million in 2025, though net losses widened to $134.1 million due to higher R&D and SG&A expenses. The company maintained a cash position of $162.8 million as of September 30, 2026, supported by approximately $81.7 million in net proceeds from common stock issuances during the year.
SHF Holdings, Inc. reported cash and cash equivalents of $4.40 million as of September 30, 2026, a decrease from $6.78 million at the end of 2025. The filing highlights significant risks including substantial doubt about the company's ability to continue as a going concern and potential impacts from the federal rescheduling of cannabis.
WhiteHorse Finance, Inc. reported a net increase in net assets resulting from operations of $16.2 million for the nine months ended September 30, 2026, compared to $6.0 million in the prior year. Total investment income decreased to $45.1 million from $55.3 million, while net asset value per share improved to $11.82 from $11.68 at year-end 2025.
Neurogene Inc. reported third quarter 2026 financial results and provided a clinical update on its NGN-401 gene therapy program for Rett syndrome. The company expects topline data from its Embolden registrational trial in the second half of 2027 and confirmed its cash runway extends into the first quarter of 2029.
Term
Q3 2026
“During the third quarter, we continued to execute across all aspects of our NGN-401 program as we advance toward potential commercialization. With topline data from the Embolden registrational trial expected in the second half of 2027, we are progressing key BLA and commercial-readiness activities, including PPQ runs that we believe remain on track for completion this year.”
Rachel McMinn, Ph.D., Founder and Chief Executive Officer
SHF Holdings reported Q3 2026 revenue of $1.95 million, a 6.5% increase year-over-year, driven by a 70.2% surge in loan program income. The company's operating loss narrowed by 17.7% to $1 million as average client deposits rose to $112 million. Management noted that while the operating platform is strengthening, they remain focused on addressing challenges related to the company's capital structure and public listing.
Term
Q3 2026
“Our third-quarter results demonstrate the continued value of Safe Harbor’s established financial services platform, with higher revenue, significant growth in loan program income and increased client deposit balances.”
Terry Mendez, Chief Executive Officer of Safe Harbor
“At the same time, we recognize the challenges facing our capital structure and public listing and remain focused on evaluating solutions that preserve the value of our operating business.”
Terry Mendez, Chief Executive Officer of Safe Harbor
Heron Therapeutics reported Q3 2026 net revenue of $35.3 million, a 7.8% decrease year-over-year, driven by a decline in its Oncology franchise despite growth in Acute Care products ZYNRELEF and APONVIE. The company also announced a definitive agreement to sell substantially all of its assets to CorMedix Therapeutics, subject to stockholder approval. Heron ended the quarter with $23.4 million in cash and cash equivalents and did not provide forward financial guidance.